AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00000626
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000626
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000626
Drug: Bleomycin sulfate
RxNorm normalized name: Bleomycin Sulfate
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05702073
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
Trial: NCT05106504
Drug: Medical Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assessed before and after use of Medical cannabis via inhaled dried buds or sublingual oil extract
Trial: NCT04741698
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol 2mg IV
Trial: NCT05794243
Drug: Sodium Caprate (C10)
RxNorm normalized name: octyl caprate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04668222
Drug: Liu-Wei-Di-Huang formula
RxNorm normalized name: di-isopropylammonium
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.
Trial: NCT04766476
Drug: BMS-963272
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05274802
Drug: ALS-4
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ALS-4 before Breakfast
Trial: NCT05274802
Drug: ALS-4
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
Trial: NCT05274802
Drug: ALS-4
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of ALS-4 up to two times daily
Trial: NCT06439225
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m2 q21 days
Trial: NCT06439225
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC5 q21 days
Trial: NCT04843982
Drug: Esketamine hydrochloride
RxNorm normalized name: esketamine hydrochloride
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
Trial: NCT06800248
Drug: emodepside (BAY 44-4400)
RxNorm normalized name: Emodepside
DrugBank: Emodepside (DB11403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with single dose of oral 15 mg emodepside
Trial: NCT06800248
Drug: Mebendazole 100 MG
RxNorm normalized name: mebendazole 100 MG
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days
Trial: NCT06800248
Drug: similar placebo to mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
Trial: NCT06800248
Drug: matching placebo of emodepside
RxNorm normalized name: Emodepside
DrugBank: Emodepside (DB11403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with single dose of oral emodepside matching placebo
Trial: NCT06397027
Drug: Ziftomenib
RxNorm normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06397027
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT06397027
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT06444113
Drug: Ofatunumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.
Trial: NCT06760403
Drug: Hypochlorous acid
RxNorm normalized name: Hypochlorous acid
DrugBank: Hypochlorous acid (DB14135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypochlorous acid, chlorhexidine and saline groups were compared as postoperative gargles after gingivectomy surgery.
Trial: NCT05109052
Drug: PXS-5505 and Atezolizumab and Bevacizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Open label safety and tolerability assessment of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab
Trial: NCT04689815
Drug: Oral Arsenic Trioxide Formulation
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
Trial: NCT05024734
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin is also the default drug, in case of failure of drug prediction in the in-vitro drug screen in PDO.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin.
Trial: NCT05024734
Drug: Mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions
Trial: NCT05024734
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation.
Trial: NCT05024734
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7.
Trial: NCT05965440
Drug: impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients
RxNorm normalized name: Gel-One
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Analysis of microbiota
Trial: NCT06132503
Drug: LP-284
RxNorm normalized name: LP-284
DrugBank: LP-284 (DB18006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.
Trial: NCT05559879
Drug: Cabo + Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combination of standard dose of cabozantinib and 500 mg dostarlimab for first 4 cycles followed by standard dose of cabozantinib and 1000 mg of dostarlimab until 2 years of treatment
Trial: NCT05086939
Drug: Autologous MSCs
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection 40 million/4 ml.
Trial: NCT05086939
Drug: Allogenic MSCs
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection 40 million/4 ml.
Trial: NCT05086939
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-articular injection 60mg / 3 ml .
Trial: NCT05035576
Drug: OPN-019
RxNorm normalized name: anti-Tlr2 monoclonal antibody OPN-305
DrugBank: Tomaralimab (DB15415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg OPN-019, 2 sprays per nostril (one dose)
Trial: NCT05853627
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
Trial: NCT04590664
Drug: Verteporfin
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT06218069
Drug: Sasanlimab
RxNorm normalized name: Sasanlimab
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL of the study drug will be administered subcutaneous injection in the abdominal fat fold. If SC injections in the abdominal location are not possible, SC injections can be administered in a distributed manner in the thighs. SC injections in the upper extremities (eg, deltoid, upper and lower arm) are not permitted. Any observed abnormality at the injection site (e.g. erythema, induration, ecchymosis, injection site pain, injection site pruritus) will be monitored and judged by the investigator to determine whether a corresponding AE should be reported.
Trial: NCT06218069
Drug: [89Zr]Zr-crefmirlimab berdoxam
DrugBank: Crefmirlimab (DB17577)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to sasanlimab injection and prior to surgery, \[89Zr\]Zr-crefmirlimab berdoxam (1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89) will be administered via an intravenous catheter. After 21-27 hours after injection patient will undergo a whole-body PETscan te detect CD8+ T-cell infiltration.
Trial: NCT04656275
Drug: BI 1323495
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1323495
Trial: NCT04991324
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24,000 IU cholecalciferol
Trial: NCT04713202
Drug: Telotristat ethyl
RxNorm normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telotristat Ethyl, 250mg
Trial: NCT04713202
Drug: Peptide Receptor Radionuclide Therapy
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide Receptor Radionuclide Therapy
Trial: NCT04687631
Drug: mFOLFOXIRI plus Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
Trial: NCT04687631
Drug: mFOLFOXIRI Plus Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab 5mg/kg + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
Trial: NCT06413433
Drug: Solriamfetol 150 mg
RxNorm normalized name: solriamfetol 150 MG
DrugBank: Solriamfetol (DB14754)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solriamfetol tablets, taken once daily
Trial: NCT06413433
Drug: Solriamfetol 300 mg
DrugBank: Solriamfetol (DB14754)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solriamfetol tablets, taken once daily
Trial: NCT05732662
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg,q3w
Trial: NCT05493618
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
Trial: NCT05493618
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab 2.5 mg/kg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
Trial: NCT05493618
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 40 mg IV q3 weeks (20 mg if patient \>75) until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
Trial: NCT05561010
Drug: Intra-articular injection of bupivacaine in the knee joint
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 participants will be allocated to the bupivacaine arm.
Trial: NCT04965402
Drug: BMS-986166
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04680442
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.
Trial: NCT04680442
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer
Trial: NCT04680442
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.
Trial: NCT06629818
Drug: Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: qw cycle 1-2, q2w cycle 3-6, q4w cycle 7-12
Trial: NCT06629818
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400mg po qd for 1 year
Trial: NCT06629818
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20mg po qw for the first 6 months, then 10mg po qw for the next 6 months
Trial: NCT06483074
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: empagliflozin oral 10mg daily for 6 months
Trial: NCT05562947
Drug: Ranibizumab (10 mg/mL)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants in the IVT arm will receive their first IVT injection of 50 μL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterward, participants will receive IVT ranibizumab injections of 50 μL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44.
Trial: NCT00266552
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05587673
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose steroid injected directly into the inflamed bowel segment(s) via its arterial blood supply.
Trial: NCT06611592
Drug: Pramipexole 0.18 mg/tid
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2 -Week 16 (end of treatment): oral administration of 0.18 mg/tid dose of pramipexole (0.25 mg salt).
Trial: NCT06611592
Drug: Pramipexole 0.35 mg/tid
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2: oral administration of a 0.18 mg/tid dose of pramipexole (0.25 mg salt).~Week 3 - Week 16 (end of treatment): oral administration of a 0.35 mg/tid dose of pramipexole (0.50 mg salt).
Trial: NCT04433845
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label
Trial: NCT05497700
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus injection of 6 mg ephedrine to keep mean arterial blood pressure above 65 mm Hg
Trial: NCT00004582
Drug: Lopinavir/Ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00004582
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05573373
Drug: Parimparib
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage and protocol of the drug were carried out according to the description.
Trial: NCT05573373
Drug: Chemotherapy drug
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage and protocol of the drug were carried out according to the description.
Trial: NCT06529523
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive standard dose of tislelizumab 200mg IV flat dose q3weeks until disease progression, unacceptable toxicity, patient/physician decides to withdraw patient, death, or completion of 104 weeks treatment (35 administrations).
Trial: NCT05187403
Drug: Laquinimod
RxNorm normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye-drops
Trial: NCT06007573
Drug: The control group received oral nimodipine tablets
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group received oral nimodipine tablets
Trial: NCT04826003
Drug: Cibisatamab
RxNorm normalized name: Cibisatamab
DrugBank: Cibisatamab (DB17349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibisatamab will be administered to participants at a fixed dose of 100 mg Q3W (100 mg on Day 1 of each 21-day cycle).
Trial: NCT04826003
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab will be administered (IV) as pre-treatment on Day - 8/- 7 (split dose) or~- 8 (single dose) prior to C1D1 of cibisatamab and as re-treatment every 6 months if the participant is still receiving cibisatamab
Trial: NCT05257941
Drug: IT Injection
RxNorm normalized name: chymopapain 4 unit INJECTION VIAL (EA)
DrugBank: Chymopapain (DB06752)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid
Trial: NCT05257941
Drug: ESP Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back
Trial: NCT06435039
Drug: APL-1202
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APL-1202 IR tablets.
Trial: NCT06435039
Drug: APL-1501
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APL-1501 ER capsules.
Trial: NCT05315947
Drug: brivaracetam
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Study participants will receive a single-dose of brivaractam tablet (reference - Treatment A) administered orally.
Trial: NCT05315947
Drug: brivaracetam
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Study participants will receive a single-dose of brivaractam dry syrup (test - Treatment B) administered orally.